Improving the identification of frail elderly newly diagnosed multiple myeloma patients

Claudia A M Stege; Kazem Nasserinejad; Saskia K Klein; Gert-Jan Timmers; Mels Hoogendoorn; Paula F Ypma; Inger S Nijhof; Gerjo A Velders; Leonie Strobbe; Nazik Durdu-Rayman; Matthijs Westerman; Marjan A Davidis-van Schoonhoven; Roel J W van Kampen; Aart Beeker; Ad Koster; Amanda C Dijk; Niels W C J van de Donk; Ellen van der Spek; Rineke B L Leys; Matthijs H Silbermann; Kaz Groen; Nicole C H P van der Burg-de Graauw; Harm A M Sinnige; Klaas G van der Hem; Henriette Levenga; Yavuz M Bilgin; Pieter Sonneveld; Mark-David Levin; Sonja Zweegman

doi:10.1038/s41375-021-01162-z

Improving the identification of frail elderly newly diagnosed multiple myeloma patients

Leukemia. 2021 Sep;35(9):2715-2719. doi: 10.1038/s41375-021-01162-z. Epub 2021 Feb 15.

Authors

Claudia A M Stege^#¹, Kazem Nasserinejad^#², Saskia K Klein^{3

4}, Gert-Jan Timmers⁵, Mels Hoogendoorn⁶, Paula F Ypma⁷, Inger S Nijhof⁸, Gerjo A Velders⁹, Leonie Strobbe¹⁰, Nazik Durdu-Rayman¹¹, Matthijs Westerman¹², Marjan A Davidis-van Schoonhoven¹³, Roel J W van Kampen¹⁴, Aart Beeker¹⁵, Ad Koster¹⁶, Amanda C Dijk¹⁷, Niels W C J van de Donk⁸, Ellen van der Spek¹⁸, Rineke B L Leys¹⁹, Matthijs H Silbermann²⁰, Kaz Groen⁸, Nicole C H P van der Burg-de Graauw²¹, Harm A M Sinnige²², Klaas G van der Hem²³, Henriette Levenga²⁴, Yavuz M Bilgin²⁵, Pieter Sonneveld²⁶, Mark-David Levin²⁷, Sonja Zweegman⁸

Affiliations

¹ Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands. c.stege@amsterdamumc.nl.
² Department of Hematology, HOVON Data Center, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
³ Department of Internal Medicine, Meander Medical Center, Amersfoort, the Netherlands.
⁴ Department of Hematology, University Medical Center Groningen, Groningen, the Netherlands.
⁵ Department of Internal Medicine, Amstelland Hospital, Amstelveen, the Netherlands.
⁶ Department of Hematology, Medical Center Leeuwarden, Leeuwarden, the Netherlands.
⁷ Department of Hematology, Haga Hospital, The Hague, the Netherlands.
⁸ Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands.
⁹ Department of Internal Medicine, Ziekenhuis Gelderse Vallei, Ede, the Netherlands.
¹⁰ Department of Internal Medicine, Gelre Hospital, Zutphen, the Netherlands.
¹¹ Department of Internal Medicine-Hematology, Franciscus Hospital location Vlietland, Schiedam, the Netherlands.
¹² Department of Internal Medicine, Northwest Clinics, Alkmaar, the Netherlands.
¹³ Department of Internal Medicine, Beatrix Hospital, Gorinchem, the Netherlands.
¹⁴ Department of Internal Medicine/Hematology, Zuyderland Medical Center, Sittard-Geleen, the Netherlands.
¹⁵ Department of Internal Medicine, MBA Spaarne Gasthuis, Hoofddorp, the Netherlands.
¹⁶ Department of Internal Medicine, VieCuri Medical Center, Venlo, the Netherlands.
¹⁷ Department of Internal Medicine, St Jansdal Hospital, Harderwijk, the Netherlands.
¹⁸ Department of Internal Medicine, Rijnstate Hospital, Arnhem, the Netherlands.
¹⁹ Department of Hematology and Oncology, Maasstad Ziekenhuis, Rotterdam, the Netherlands.
²⁰ Department of Internal Medicine, Tergooi Hospital, Hilversum, the Netherlands.
²¹ Department of Internal Medicine, Bravis ziekenhuis, Roosendaal, the Netherlands.
²² Department of Internal Medicine, Jeroen Bosch Ziekenhuis, 's Hertogenbosch, the Netherlands.
²³ Department of Internal Medicine, Zaans Medical Center, Zaandam, the Netherlands.
²⁴ Department of Internal Medicine, Groene Hart Hospital, Gouda, the Netherlands.
²⁵ Department of Internal Medicine, Admiraal de Ruijter Hospital, Goes, the Netherlands.
²⁶ Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
²⁷ Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, the Netherlands.

^# Contributed equally.

PMID: 33589752
DOI: 10.1038/s41375-021-01162-z

No abstract available

Publication types

Clinical Trial, Phase II
Multicenter Study
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Follow-Up Studies
Geriatric Assessment / methods*
Humans
Multiple Myeloma / drug therapy
Multiple Myeloma / mortality*
Multiple Myeloma / pathology
Prognosis
Prospective Studies
Survival Rate